CERo Therapeutics Holdings, Inc. (CERO) stock
CEROOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as CEROW
$0.01+0.00 (0.00%)
Close on Oct 19, 2026Market cap $253.05KP/E –Yield 172833.33%
CERo Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
CERo Therapeutics's operating income for the twelve months ending Dec 31, 2023 was -$7.68M. For fiscal 2023 it was -$7.68M.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | -$7.68M | – |
| FY2022 | Dec 31, 2022 | -$2.91M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$3.85M | – |
| Q1 FY2026 | Mar 31, 2026 | -$4.85M | – |
| Q3 FY2025 | Sep 30, 2025 | -$4.36M | – |
| Q2 FY2025 | Jun 30, 2025 | -$4.72M | – |
| Q1 FY2025 | Mar 31, 2025 | -$4.95M | – |
| Q3 FY2024 | Sep 30, 2024 | -$4.40M | – |
| Q2 FY2024 | Jun 30, 2024 | -$5.15M | – |
| Q4 FY2023 | Dec 31, 2023 | -$1.12M | – |
| Q3 FY2023 | Sep 30, 2023 | -$1.54M | – |
| Q2 FY2023 | Jun 30, 2023 | -$2.41M | – |
| Q1 FY2023 | Mar 31, 2023 | -$2.44M | – |
| Q4 FY2022 | Dec 31, 2022 | -$1.29M | – |
| Q3 FY2022 | Sep 30, 2022 | -$836.69K | – |
| Q2 FY2022 | Jun 30, 2022 | -$376.58K | – |
See a number that looks wrong?